Two other PI3K inhibitors, that is duvelisib (PI3Kγ/δ inhibitor) and copanlisib (pan-PI3K inhibitor), have also found approval for the treatment of leukemia and lymphoma [26]. This evidence concerns the gene PIK3CA and leukemia.